Yihui Song

Key Laboratory Of Gastrointestinal Cancer
Fuzhou, 350122, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Unveiling New Binding Sites and Allosteric Regulation Mechanisms of LSD1 for Novel Therapeutics.

Unveiling New Binding Sites and Allosteric Regulation Mechanisms of LSD1 for Novel Therapeutics.

Journal: Journal of medicinal chemistry

Published: May 16, 2025

Ubiquitin-Specific Protease 7 (USP7) as a Promising Therapeutic Target for Drug Discovery: From Mechanisms to Therapies.

Ubiquitin-Specific Protease 7 (USP7) as a Promising Therapeutic Target for Drug Discovery: From Mechanisms to Therapies.

Journal: Journal of medicinal chemistry

Published: April 16, 2025

Structure-Guided Design of Pyrazolopyrimidinones as Highly Potent and Selective Allosteric SHP2 Inhibitors.

Structure-Guided Design of Pyrazolopyrimidinones as Highly Potent and Selective Allosteric SHP2 Inhibitors.

Journal: Journal of medicinal chemistry

Published: April 16, 2025

JBI-802: the first orally available LSD1/HDAC6 dual inhibitor to enter clinical trials.

JBI-802: the first orally available LSD1/HDAC6 dual inhibitor to enter clinical trials.

Journal: Expert opinion on therapeutic patents

Published: February 17, 2025

Leveraging non-enzymatic functions of LSD1 for novel therapeutics.

Leveraging non-enzymatic functions of LSD1 for novel therapeutics.

Journal: Trends in pharmacological sciences

Published: November 21, 2024

Unravelling the target landscape of tranylcypromines for new drug discovery.

Unravelling the target landscape of tranylcypromines for new drug discovery.

Journal: Acta pharmaceutica Sinica. B

Published: September 12, 2024

Emerging therapeutic approaches of SHP2-targeted modulators.

Emerging therapeutic approaches of SHP2-targeted modulators.

Journal: Future medicinal chemistry

Published: January 26, 2024

Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor.

Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor.

Journal: Acta pharmaceutica Sinica. B

Published: December 13, 2023

Recent advances of LSD1/KDM1A inhibitors for disease therapy.

Recent advances of LSD1/KDM1A inhibitors for disease therapy.

Journal: Bioorganic chemistry

Published: December 25, 2022

Development of a robust HTRF assay with USP7 full length protein expressed in E. coli prokaryotic system for the identification of USP7 inhibitors.

Development of a robust HTRF assay with USP7 full length protein expressed in E. coli prokaryotic system for the identification of USP7 inhibitors.

Journal: Journal of pharmaceutical and biomedical analysis

Published: December 25, 2022

Harnessing the cyclization strategy for new drug discovery.

Harnessing the cyclization strategy for new drug discovery.

Journal: Acta pharmaceutica Sinica. B

Published: August 10, 2022

Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.

Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.

Journal: European journal of medicinal chemistry

Published: December 30, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026